Streetbeat News

Products Services

BTCY

Biotricity announces high demand for its Biotres Pro, a 3-channel patch-like ECG, expected to increase subscription prices by over 32% and revenue by up to 10% from sales to existing customers through 2025. The initial production run has sold out, with pre-orders for the next run scheduled to ship by the end of May.

Portfolio Pulse from Benzinga Newsdesk

April 26, 2024 | 11:29 am

FDCF

SNAP

SOCL

Snap Inc. (NYSE:SNAP) shares surged over 25% in premarket trading following the announcement of its first-quarter financial results, which exceeded analyst expectations. The company reported earnings of 3 cents per share against an expected loss of 5 cents per share, with adjusted EBITDA of $46 million, up from $1 million the previous year. Quarterly sales reached $1.195 billion, surpassing estimates by 6.74% and marking a 20.88% increase year-over-year. Snap also reported a 10% increase in daily active users to 422 million and introduced new tools and features. The company anticipates Q2 revenues between $1.225 billion and $1.255 billion, expecting daily active users to grow to approximately 431 million. Investors can also gain exposure to SNAP through the Global X Social Media ETF (NASDAQ:SOCL) and Fidelity Disruptive Communications ETF (NASDAQ:FDCF).

Portfolio Pulse from Nabaparna Bhattacharya

April 26, 2024 | 11:29 am

APLS

The European Medicines Agency has reset the review of Apellis Pharmaceuticals' intravitreal Pegcetacoplan for Geographic Atrophy to the last phase of the initial assessment, with an anticipated opinion from CHMP by July 2024.

Portfolio Pulse from Benzinga Newsdesk

April 26, 2024 | 11:19 am

TECH

Bio-Techne and Novomol-Dx have developed Bio-marker Pathfinder, an ocular biomarker kit for point-of-care applications, utilizing Bio-Techne's Ella platform and Novomol-Dx's proprietary algorithms. The kit, aimed at diagnosing and monitoring conditions like Dry Eye Disease and Diabetic Retinopathy, promises accurate and fast results.

Portfolio Pulse from Benzinga Newsdesk

April 26, 2024 | 11:12 am

IYT

JETS

LUV

Southwest Airlines Co (NYSE:LUV) is considering abandoning its open seating policy for assigned seats and premium options to attract younger travelers. This marks a significant shift from its traditional model since 1971. The decision is part of a broader strategy to meet evolving customer expectations, with an official announcement expected in September. Additionally, Southwest announced the closure of operations at four airports. The company's stock has declined over 11% in the past year, impacting investors in LUV and related ETFs like U.S. Global Jets ETF (NYSE:JETS) and iShares U.S. Transportation ETF (BATS:IYT).

Portfolio Pulse from Shivani Kumaresan

April 26, 2024 | 11:12 am

SATS

EchoStar Corporation announced that its subsidiary, Hughes Network Systems, has opened a new manufacturing facility and private 5G incubation center in Germantown, Maryland. This move aims to boost local talent and expand the company's capabilities in the 5G domain.

Portfolio Pulse from Benzinga Newsdesk

April 26, 2024 | 11:11 am

CHTR

Charter Communications reported a decrease of 72,000 in total residential and SMB Internet customers, totaling 30.5 million as of March 31, 2024. Conversely, their mobile lines saw an increase of 486,000, reaching 8.3 million. Overall, Charter had 32.0 million residential and SMB customer relationships, excluding mobile-only relationships.

Portfolio Pulse from Benzinga Newsdesk

April 26, 2024 | 11:08 am

CHTR

Charter Communications reported a decrease of 72,000 in Q1 residential and SMB Internet customers, but saw an increase of 486,000 in mobile lines. Total revenue for the quarter was $13.7 billion, a 0.2% increase year-over-year, with significant growth in residential mobile service and Internet revenue.

Portfolio Pulse from Benzinga Newsdesk

April 26, 2024 | 11:06 am

BMY

Bristol Myers announced that the EMA's CHMP has recommended the approval of Opdivo in combination with cisplatin and gemcitabine for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma. The European Commission will review the recommendation, with a final decision expected in June 2024.

Portfolio Pulse from Benzinga Newsdesk

April 26, 2024 | 11:04 am

PFE

Pfizer's BEQVEZ, a one-time gene therapy for adults with Hemophilia B, has received U.S. FDA approval. Pfizer plans to launch an innovative warranty program for BEQVEZ, ensuring financial protection and maximizing access for eligible patients. BEQVEZ is also under review in Europe and has been approved in Canada. Pfizer is further investigating gene therapies for hemophilia A and Duchenne muscular dystrophy, and a treatment for hemophilia A and B, marstacimab, is under review by the FDA and EMA.

Portfolio Pulse from Benzinga Newsdesk

April 26, 2024 | 10:48 am